Alogliptin: a new addition to the class of DPP-4 inhibitors by Andukuri, Radha et al.
© 2009 Andukuri et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 117–126
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
117
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Alogliptin: a new addition to the class 
of DPP-4 inhibitors
radha Andukuri 
Andjela Drincic 
Marc rendell
Division of endocrinology, 
Department of Medicine, Creighton 
University School of Medicine, 
Omaha, Nebraska, USA
Correspondence: Marc rendell  
Creighton Diabetes Center, 601 North 
30th Street, Omaha, Ne 68131, USA 
Fax +1 402-280-5655 
email rendell@asndi.com
Background: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the 
enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin 
hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) by preventing their degradation.
Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, 
clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 
inhibitors.
Methods: A comprehensive literature search was performed using the term ‘alogliptin’. Original 
research articles and review articles as well as scientific abstracts were included.
Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibit-
ing a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all 
doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 
0.5% to 0.6%. Combination therapy yielded similar reductions (−0.5% with metformin, −0.6% 
with glyburide, −0.8% with pioglitazone and –0.6% with insulin). Administration of alogliptin 
does not promote weight loss but has not resulted in weight gain. The agent is relatively well 
tolerated with few adverse effects, the major finding being a marginally higher rate of skin 
events, primarily pruritus.
Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combi-
nation with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors 
in current clinical use. The side effect profile also does not differ from that of other DPP-4 
inhibitors. However, long-term studies are necessary before the place of alogliptin in the man-
agement of type 2 diabetes can be established.
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Introduction
Type 2 diabetes mellitus is a disorder of blood glucose control owing to multiple 
metabolic abnormalities, including insufficient insulin secretion, impaired response 
of liver and peripheral tissues to insulin (insulin resistance), progressive loss of beta-
cell function, disregulation of glucagon secretion and disturbed incretin hormone 
physiology.1 The prevalence of diabetes is increasing worldwide from estimated 
2.8% in 2000 to 4.4% in 2030.2 The total number of people with diabetes is projected 
to rise from 171 million in 2000 to 366 million in 2030.2 While tight control of dia-
betes substantially decreases the risk of microvascular complications,3 only 37% of 
patients currently reach the target hemoglobin A1c (HbA1c) of 7%, goal set by the 
American Diabetes Association.4 The choice of agents to improve blood glucose Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 118
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levels includes metformin, sulfonylureas, disaccharidase 
inhibitors, thiazolidinediones and insulin. Two new classes 
of agents which target the incretin system have recently come 
into clinical use. These are the GLP -1 receptor agonists and 
dipeptidyl peptidase-4 (DPP-4) inhibitors.
The incretin system
Incretins are hormones secreted by the gut in response to 
oral nutrient intake. Incretin secretion results in an aug-
mentation of insulin secretion over and above the response 
solely attributable to the rise in intravenous glucose con-
centration. Two incretin hormones are of particular interest: 
glucagon-like polypeptide (GLP-1) and glucose-dependent 
insulinotropic peptide, also known as gastric inhibitory 
polypeptide (GIP). GIP and GLP-1 are both secreted within 
minutes of food consumption and act through distinct 
receptors.5,6,7 Both peptides act on pancreatic beta-cells 
to stimulate glucose-dependent insulin secretion, induc-
tion of beta-cell proliferation, and enhance resistance to 
apoptosis. Both GIP and GLP-1 are rapidly degraded by 
the enzyme DPP-4.
GIP is the first incretin to be discovered.8 It is secreted 
proximally from the K cells of the gut in response to oral 
ingestion of food containing glucose and fat. GIP promotes 
a glucose-dependent insulin secretion. GIP also promotes 
energy storage by adipocytes and enhances bone formation 
via stimulation of osteoblast proliferation and inhibition of 
apoptosis.6 Effects of GIP include incorporation of fatty acids 
into triglycerides, stimulation of lipoprotein lipase activity, 
modulation of fatty acid synthesis8 and promotion of beta-cell 
proliferation and survival.9,10 Plasma concentrations of GIP 
are reported to be normal or increased in diabetes,11,12 but the 
insulinotropic effect is deficient. This is thought to be due to 
downregulation of GIP expression/activity.13,14
GLP-1 is a 30/31 amino acid peptide secreted from the 
L cells of the distal gut into the capillaries and then into the 
blood stream. It is quickly metabolized by DPP-4 giving 
active GLP-1 a half-life of only 1 to 2 minutes. Despite its 
short life, GLP-1 reaches the pancreatic beta-cell causing a 
glucose-dependent increase in insulin secretion. Other effects 
of GLP-1 include suppression of glucagon secretion, slowing 
of gastric emptying time and promotion of satiety.15 GLP-1 
also promotes differentiation and proliferation of beta-cells 
and inhibition of apoptosis, thus offering the potential to 
reverse the effects of diabetes on beta-cell mass. GLP-1, 
but not GIP, controls glycemia via additional actions on 
inhibition of gastric emptying, food intake and glucagon 
secretion.7 Postprandial GLP-1 release is about 25% to 30% 
lower in patients with type 2 diabetes and those with impaired 
glucose tolerance.16 In addition, the insulinotropic effect of 
GLP-1 is blunted in diabetes,17,18 perhaps in part related to 
glucagon levels.19,20 GLP-1 infusions have shown more prom-
ising results than those of GIP in lowering plasma glucose 
in diabetes.21,22 GLP-1 also promotes satiety, and sustained 
GLP-1-receptor activation is associated with weight loss in 
both preclinical and clinical studies.
Incretin pathway effects can be enhanced in two ways: 
by administering GLP-1 agonists, or by slowing their 
degradation with DPP-4 inhibitors. Several studies have now 
shown that GLP-1 can lower glucose levels even in patients 
with severe beta-cell impairment, presumably as a result 
of lowered glucagon levels and other non insulin related 
effects.23 Subcutaneous infusion of GLP-1 resulted in lower 
overall glycemic levels than pioglitazone treatment, and the 
effect was additive.24 Treatment with the long acting GLP-1 
derivative liraglutide significantly reduced overall 24-hour 
glucose levels as well as those of glucagons.25 Continuous 
subcutaneous infusion of GLP-1 for 3 months lowered capil-
lary blood glucose levels in elderly type 2 diabetic subjects.26 
The glycemic effects of GLP-1 are associated with improve-
ment in endothelial function.27
Exendin is a reptilian peptide with affinity for the 
mammalian GLP-1 receptor and relative resistance to 
degradation, resulting in a relatively long-lasting effect.28 
Exenatide treatment has shown promising effects either 
as monotherapy29 or in combination with other agents.30–32 
Treatment with exendin-4 has reduced postprandial hyper-
glycemia in Type I diabetes, confirming that the mechanism 
of action does not rely solely on insulin secretion.33 In 272 
metformin treated patients with initial HbA1c of 8.2 ± 1.1%., 
HbA1c levels dropped by 0.8 ± 0.1% and weight decreased 
by 2.8 ± 0.5 kg after 30 weeks of treatment with 10 µg of 
exenatide.31 In 377 sulfonylurea treated subjects with initial 
HbA1c of 8.6 ± 1.2% given exenatide 10 µg twice daily, HbA1c 
dropped −0.9 ± 0.1% and weight was reduced −1.6 ± 0.3 kg 
from baseline (P  0.05 vs placebo).32 Exenatide is injectable 
and needs to be taken twice daily. There are considerable 
gastrointestinal side effects in up to 40% of patients.
An alternative to supplementation of GLP-1 is to 
inhibit the rapid degradation of this hormone by DPP-4.33,34 
Several DDP-4 inhibitors have been developed and have 
come into clinical use.35,36 Currently, sitagliptin is the only 
DPP-4 inhibitor available in the United States.37 Sitagliptin 
is effective as monotherapy38,39 and in combination with 
metformin.40–42 Sitagliptin is generally well tolerated with 
an overall incidence of adverse experiences comparable to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 119
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placebo, a low risk of hypoglycemia and gastrointestinal 
problems, and a neutral effect on body weight.43
Vildagliptin is approved in Europe and in Latin 
America.44 It is efficacious as monotherapy45 and in combina-
tion with metformin.46 In a comparison study of vildagliptin 
vs metformin in drug-naïve patients with type 2 diabetes, 
metformin treatment resulted in greater weight loss and 
a superior glucose-lowering effect, but had a higher inci-
dence of gastrointestinal side effects.47 Vildagliptin added 
to metformin therapy provides a modest reduction in HbA1c 
comparable to that of glimepiride but without the signifi-
cant weight gain and hypoglycemia which occurs with the 
sulfonylureas.48 Inhibition of GLP-1 and GIP by DPP-4 
inhibitors such as vildagliptin and sitagliptin result in signifi-
cant improvements in glucose levels in patients with type 2 
diabetes. The glucose-lowering effect of currently available 
DPP-4 inhibitors appears to be somewhat less than those 
of exenatide and, unlike exenatide, there is no beneficial 
weight loss.49,50
Recently a new DPP-4 inhibitor alogliptin has been 
developed. It is our purpose to review the properties of 
alogliptin and its potential benefits in treating diabetes.
Pharmacokinetics  
and pharmacodynamics of alogliptin
Alogliptin benzoate is an orally available quinazolinone-
based noncovalent inhibitor of DPP4.49 It is a highly potent, 
highly selective, orally available DPP-4 inhibitor. Its selectiv-
ity for DPP-4 is 10,000-fold greater than that of the other 
DPP isozymes 2/8/9.51,52
Metabolism
Disposition of alogliptin was studied in eight healthy volun-
teers given a dose of 25 mg.53 It is rapidly absorbed as early 
as 15 minutes with a Tmax of 2 hours. The mean volume of 
distribution of alogliptin was 60.9 L, greater than that of 
body water (42 L), indicating that it is well distributed in all 
tissues. Approximately 85% of plasma radioactivity, 95% 
of urine radioactivity and 88% of fecal radioactivity was 
accounted for by the parent compound suggesting minimal 
metabolism.53 It is metabolized to two minor metabolites. 
M-1, an N-demethylated metabolite and M-2, an N-acetylated 
metabolite. M-1 an M-2 are formed and represent 2% and 
6% respectively, of parent drug concentrations in plasma 
and urine.
The pharmacokinetic and pharmacodynamic profiles of 
alogliptin in healthy subjects were evaluated with single 
doses of 6.25 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 
400 mg, and 800 mg.54 Multiple-dose studies were done in 
subjects with type 2 diabetes and doses of 25 mg, 100 mg 
and 400 mg were given for 14 days.55 Alogliptin is rapidly 
absorbed after oral administration with median Tmax ranging 
from 1 to 2 hours across all doses. Mean half-life was 12.4 
to 21.4 hours across all doses.54
DPP-4 inhibition
DPP-4 enzyme activity and active GLP-1 levels were mea-
sured in human studies after single and multiple doses of 
alogliptin.54,55 Mean plasma DPP-4 inhibition after a single 
dose of alogliptin (25 mg to 800 mg) ranged from 74.3% 
to 94% at 24 hours and 47.5% to 83% at 72 hours.54 After 
14 days of dosing (25 mg to 400 mg), mean peak DPP-4 
inhibition ranged from 94% to 99% and mean inhibition at 
24 hours after dosing ranged from 82% to 97% across all 
doses. Plasma DPP-4 activity was inhibited by 80% after 
24 hours, supporting a once daily regimen.55 An increase of 
2- to 4-fold in active GLP-1 levels in response to alogliptin 
occurs and is most evident after meals.55 This is similar to 
GLP-1 values observed with sitagliptin treatment.37
excretion
Alogliptin is primarily excreted unchanged in the urine 
accounting for ∼60% to 71% of the administered dose. 
Mean clearance (165 to 254 mL/min) across doses slightly 
exceeded the GFR (glomerular filtration rate) suggesting 
some renal secretion.53 The fact that it is excreted unchanged 
through the kidney raises concern for possible interaction 
with other renally excreted drugs like metformin. However, 
a multiple-dose drug interaction study done with alogliptin 
and metformin found no pharmacokinetic interaction.56
Drug interaction studies
In addition to metformin, drug interaction studies were 
done with other common antidiabetic agents ( glyburide,57 
and pioglitazone.58 Studies with CYP inhibitors disclosed 
no significant interactions with fluconazole, ketoconazole 
and gemfibrozil.59 Other interaction studies with warfarin,60 
cyclosporine,61 ethinylestradiol and norethindrone,62 
atorvastatin,63 and digoxin64 were also reassuring.
Efficacy
Alogliptin monotherapy
Alogliptin has been studied as both monotherapy and in 
combination with other oral agents in type 2 diabetes patients 
with HbA1c between 7% and 10%. DeFronzo et al evalu-
ated alogliptin as monotherapy for treatment-naïve patients Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 120
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with type 2 DM for 26 weeks.65 Mean HbA1c decreased 
significantly with 12.5 mg (−0.56%) and 25 mg (−0.59%) 
compared with placebo (−0.02%). Fasting plasma glucose 
improved within a week and HbA1c within 4 weeks. Differ-
ences in fasting plasma glucose from placebo at week 26 
were significant at −22 mg/dL and −28 mg/dL with 12.5 mg 
and 25 mg respectively.65
Sulfonylurea add-on
Pratley et al evaluated combination therapy of alogliptin 
added to glyburide (mean dose was 11.2 to 12.4 mg) and 
showed significant HbA1c reductions across increasing doses 
of alogliptin: –0.39% with 12.5 mg, and –0.53% with 25 mg 
compared with placebo (+0.01%).66 Reductions were seen 
as early as 4 weeks and continued throughout the 26-week 
period. More patients in the alogliptin group achieved HbA1c 
reductions of 0.5% (26.3% with placebo, 47.3% with 
12.5 mg and 50.5% with 25 mg of alogliptin; P  0.001). 
Similarly more patients in the alogliptin arm had HbA1c 
reductions of 1% compared with placebo (13.1% with 
placebo, 18.7% with 12.5 mg and 29.8% with 25 mg of 
alogliptin; P  0.001 for 25 mg and 0.149 for 12.5 mg). The 
improvement was noted primarily in postprandial glucose 
since the mean change in fasting plasma glucose was small 
and non significant across all groups.66
Metformin add-on
Nauck et al assessed the efficacy of alogliptin as an 
add-on to metformin therapy for 26 weeks.67 Mean HbA1c 
reductions noted with placebo, alogliptin 12.5 mg and 25 mg 
were −0.1%, −0.6% and −0.6% respectively (P  0.001). 
Reductions in fasting plasma glucose were observed at all 
metformin doses and were significant in patients receiving 
either dose of alogliptin compared with placebo: 0 mg/dL, 
−19 mg/dL and −17 mg/dL with placebo, alogliptin 12.5 mg 
and 25 mg respectively.67
Pioglitazone (TZD) add-on
Alogliptin was utilized as add-on therapy for patients on 
thiazolidinediones (pioglitazone) with or without met-
formin and sulfonylurea and followed for 26 weeks.68 
Reductions in HbA1c were: −0.19%, −0.66% and −0.80% 
for placebo, 12.5 mg and 25 mg of alogliptin respectively 
(P  0.001). Meaningful reductions were seen regardless 
of the dose of pioglitazone and with or without sulfonylurea 
or metformin. Mean differences in fasting plasma glucose 
from placebo were −14 mg/dL with both 12.5 mg and 25 mg 
(P  0.001).68
insulin add-on
In a double-blind placebo-controlled study, 390 subjects on 
insulin with or without metformin were randomized to receive 
alogliptin at 12.5 mg or 25 mg and followed for 26 weeks.69 
Subjects on very high insulin doses (100 units /day) and 
HbA1c  8% were excluded. The mean dose of insulin was 
56.5 units/day and mean HbA1c was 9% at the entry. The 
addition of alogliptin resulted in HbA1c reduction of −0.51% 
and −0.59% and was significant (P  0.001 for both doses. 
Reductions were seen regardless of the insulin dose and 
whether or not they were on metformin. Mean FPG reduc-
tions from placebo were −4 mg/dL and −18 mg/dL for 
12.5 mg and 25 mg respectively.69
Effects on pancreatic beta-cell 
function
In the 26-week randomized double-blind placebo-controlled 
study done by DeFronzo with alogliptin, modest apparent 
increases in proinsulin:insulin ratio and beta-cell function 
determined by homeostasis model assessment (HOMA-β) 
did not achieve statistical significance.65 Similar results were 
observed by Pratley et al evaluating efficacy of alogliptin with 
glyburide. Improvements in measurement of beta-cell func-
tion (as measured by fasting insulin concentration, proinsulin 
to insulin ratio and HOMA-β) were not clinically significant 
(P  0.124) (66). In the study evaluating metformin and 
alogliptin by Nauck et al a trend towards lower proinsulin:
insulin ratio was observed with alogliptin.67 In summary, 
alogliptin, like other DPP-4 inhibitors, could theoretically 
preserve beta-cell function, but long-term studies will be 
needed to prove this to be true.
Effects on lipids
Effects on lipid parameters, evaluated across the alogliptin 
studies, have been minor. Changes in LDL were –3.2 mg/dL 
compared with placebo and +3.9 mg/dL (P = 0.044) in 
monotherapy and in combination therapy with glyburide.65,66 
The effects on other lipid parameters were non significant.65 
In add-on therapy to metformin, there have been no signifi-
cant effects on lipid profiles.67
Effects on weight
Weight changes noted when alogliptin was used in mono-
therapy in doses of 12.5 mg or 25 mg have not been clini-
cally or statistically significant.65 Minor increases in weight 
were seen when alogliptin was added to the background of 
sulfonylurea: –0.2 kg placebo, +0.6 kg alogliptin 12.5 mg 
(P = 0.018) and +0.68 kg for alogliptin 25 mg (P = 0.010).66 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 121
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Alogliptin proved to be weight neutral when added to 
metformin. Mean differences in weight relative to placebo 
were 0.0 kg and –0.3 kg for 12.5 mg and 25 mg respectively.67 
These results showing minor increases in mean weight are 
consistent with the results from previous studies done with 
other DPP-4 inhibitors, sitagliptin (+0.7 kg, P = 0.008) and 
vildagliptin (+0.8 kg, P = 0.009).70
A summary of the clinical efficacy of alogliptin as mono-
therapy and combination therapy is included in Table 1.
Efficacy of alogliptin compared 
to other DPP-4 inhibitors
There is much experience with the other available DPP-4 
inhibitors sitagliptin and vildagliptin. However, there are 
no head-to-head studies reported comparing sitagliptin and 
vildagliptin, nor have there been studies comparing alogliptin 
with these currently approved DPP-4 inhibitors. Caution 
must therefore be exercised in judging relative efficacy. 
A meta-analysis comparing sitagliptin and vildagliptin with 
placebo showed that they resulted in significant reduction of 
HbA1c values, –0.6% with sitagliptin (95% CI –0.8 to −0.4, 
P  0.00001) and –0.7% with vildagliptin (95% CI −0.9 
to −0.6, P  0.001).70 Combination therapy resulted in 
additional lowering of HbA1c with both agents. However, 
monotherapy with either DPP-4 inhibitor proved inferior 
in comparison to monotherapy with either metformin or 
sulfonylureas.70 Saxagliptin is another DPP-4 inhibitor under-
going phase 3 trials and is also showing placebo-adjusted 
HbA1c reductions of −0.45% to −0.63%.71,72
The improvements in HbA1c seen with alogliptin appear to 
be in the same range as with the alternative DPP-4 inhibitors.
Clinical safety
Clinical safety of alogliptin has been evaluated in multiple 
studies with doses ranging from 6.25 to 800 mg. It has also 
been studied in patients with renal and hepatic impairment.
Monotherapy
Single-dose study
Covington et al studied single increasing doses of alogliptin 
in 36 subjects.54 Thirty received alogliptin in doses ranging 
from 25 mg to 800 mg and 6 received placebo. Asymptomatic 
hypoglycemia was reported in 5 subjects (1 on 50 mg, 2 on 
200 mg, 1 on 400 mg of alogliptin and 1 on placebo). Other 
adverse events reported in one subject each include: dizzi-
ness (100 mg), syncope (200 mg), constipation (200 mg), 
viral infection (400 mg), hot flush (placebo) and nausea 
(placebo).54
Multiple-dose study
In a multiple-dose study of 56 subjects given alogliptin in 
doses ranging from 25 mg to 400 mg for 14 days, commonly 
reported adverse events included headache (6/16), dizziness 
(4/16) and constipation in 3/16. These events occurred 
primarily at the highest dose of alogliptin. There were no 
discontinuations from the study due to side effects.55
Phase 3 studies
In a 26-week study examining 329 subjects on alogliptin 
monotherapy, DeFronzo et al showed an overall incidence 
of adverse events (AEs) of 68.4% with 12.5 mg, 67.4% with 
25 mg and 70.3% with placebo.65 However, only 17.2%, 
23.3% and 22.7% were considered drug related in the 
placebo, alogliptin 12.5 mg and 25 mg groups, respectively. 
Discontinuation of therapy due to side effects occurred in 
similar proportions of patients across the treatment groups 
(1.5 to 2.3%).. Serious AEs occurred without relation to 
dose (12.5 mg: 3.8%; 25 mg: 0.8%; placebo: 3.1%) and 
were considered unrelated to the drug. Most common AEs 
were nasopharyngitis (7.8%, 9.0% and 7.6%; with placebo, 
12.5 mg and 25 mg, respectively), headache (4.7%, 7.5% and 
6.8%; with placebo, 12.5 mg and 25 mg, respectively) and 
upper respiratory tract infection (9.4%, 3.8% and 4.5%; with 
placebo, 12.5 mg and 25 mg). The incidence of hypoglyce-
mia was low and similar across groups (1.6% with placebo 
and 3.0%, 1.5% with 12.5 mg and 25 mg). Hypoglycemic 
events were not severe and did not require assistance. Skin-
related AEs, primarily pruritus, were higher in the treated 
groups (12.5 mg, 3%; 25 mg, 1.5%; 0 with placebo).65
Pratley et al studied 500 patients using alogliptin as 
add-on therapy to glyburide (66). AEs were reported in 
64% of patients treated with alogliptin 12.5 mg, and 63% 
of patients on 25 mg dose, compared with 54% in the 
placebo group. Most AEs were mild in intensity and not 
considered treatment-related. Serious AEs were reported 
in 2% of placebo-treated patients, 5.4% of patients on 
alogliptin 12.5 mg and 5.6% of patients treated with 
the 25 mg alogliptin dose. AEs that occurred in 5% 
of patients in any treatment group (including placebo) 
included upper respiratory infection, urinary tract infection, 
headache and hypertension. There was also an increased 
incidence of skin-related events, mainly pruritus (0%, 
3% and 6% with placebo, 12.5 mg and 25 mg). Gastroin-
testinal side effects occurred with the same frequency in 
the placebo and 12.5 mg groups, with a nominally higher 
incidence at 25 mg. The incidence of hypoglycemia was 
11.1% for placebo, 15.8 for alogliptin 12.5 mg and 9.6% Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 122
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for alogliptin 25 mg. Thus, addition of alogliptin did not 
increase the risk of hypoglycemia attributable to glyburide 
therapy.66
In a study of alogliptin in combination with metformin 
in 201 patients, Nauck et al found that the majority of AEs 
were unrelated to the study drug.67 The incidence of serious 
AEs was similar across treatment groups (2.8% to 3.9%). 
The incidence of hypoglycemia was low (1%) across 
all groups and there were no severe hypoglycemic events 
requiring assistance. Skin-related events occurred in 7.7% 
of patients in the placebo group, 12.2% in the 12.5 mg group 
and 11.6% in the 25 mg group. These included dry skin, rash, 
eczema and pruritus.67
In a study of alogliptin added to pioglitazone, the AE 
rates among 372 patients completing the study were: 64.9% 
with placebo, 69.7% with alogliptin 12.5 mg and 72.4% with 
alogliptin 25 mg.68 The incidence of hypoglycemia was low 
(5.2%, placebo; 5.1%, 12.5 mg; 7%, 25 mg).
Alogliptin was studied as an addition to insulin therapy in 
390 patients. Patients experiencing 1 AE (73.6%, placebo; 
67.9%, 12.5 mg; 66.7%, 25 mg) and 1 serious AE (4.7%, 
placebo; 6.1%, 12.5 mg; 5.4%, 25 mg) were similar across 
treatment groups. The incidence of severe hypoglycemia 
was low (1.6%, placebo; 0%, 12.5 mg; 0.8%, 25 mg) and 
similar across groups.69
Skin toxicity
Preclinical studies done with other DPP-4 inhibitors, vilda-
gliptin and saxagliptin, have raised the concern of necrotic 
skin lesions observed in monkeys, the mechanism of which is 
unclear.73 However such skin lesions have not been observed in 
humans, or in preclinical or clinical studies with sitagliptin74 or 
alogliptin. The relationship of the monkey skin lesions to DPP-4 
inhibition vs DPP-8/9 inhibition remains unresolved.75 Serious 
allergic and hypersensitivity reactions such as anaphylaxis, 
angioedema, and exfoliative skin conditions including Stevens-
Johnson syndrome were reported in patients treated with sita-
gliptin in post-marketing reports.76 The alogliptin studies have 
incorporated a search for skin lesions, with a marginally higher 
rate than in placebo, the major finding being pruritus.
Safety profile of alogliptin compared 
with other DPP-4 inhibitors
Like other DPP-4 inhibitors, alogliptin is well tolerated overall. 
Severe hypoglycemia requiring third-party assistance has 
not been reported in studies done on DPP-4 inhibitors. This 
is not surprising, because secretion of incretins is glucose-
dependent.77 Meta-analysis of all the available studies on 
sitagliptin and vildagliptin showed a risk of gastrointestinal 
side effects comparable to placebo. Risk of all-cause infections 
(nasopharyngitis, upper respiratory infection, urinary tract 
infection, sinusitis) was higher with sitagliptin (odds ratio 1.34, 
95% CI 1.10 to 1.64, P = 0.004), but not for vidagliptin.70 Since 
this side effect may be related to the prolonged action of another 
DPP4 substrate, substance P,78 it is possible that the same side 
effects will be noted with alogliptin as well. Vildagliptin is 
also reported to cause pedal edema which is not reported with 
alogliptin.79,80 Rare cases of hepatic dysfunction and hepatitis 
have been reported with vildagliptin, and it is recommended to 
monitor liver function tests every 3 months for the first year of 
therapy.70 Liver enzyme abnormalities have not been observed 
with alogliptin thus far. It is not known whether DPP4 selec-
tivity of alogliptin and sitagliptin, compared to vildagliptin 
(which inhibits both DPP-4 and DPP-8 enzymes), has clinical 
significance. While DPP-4 protein has a role in T-cell medi-
ated immune response, DPP-8 and DPP-9 enzymes (located in 
leukocytes) are involved in T-cell activation and the processes 
of cell adhesion, migration and apoptosis. It has been shown81 
that inhibition of DPP-8 and 9 suppresses mitogen-stimulated 
T-cell responses but DPP-4 selective inhibition does not. Again, 
the clinical significance (if any) of the DPP-4 vs DPP-8 selec-
tivity is not clear at this point, and long-term clinical follow 
up data are needed.82 At this time, it is unclear whether there 
have been sufficient cardiac events in the alogliptin-treated 
populations in the research studies to date to satisfy potential 
cardiac safety concerns.
Special populations
Patients with renal and hepatic 
impairment
Alogliptin 50 mg administered to patients with renal impair-
ment did not cause any increase in AEs.83 It was given to 
6 subjects in each group of mild, moderate, severe and end 
stage renal disease, and 25% experienced at least one AE, but 
were judged to be mild and unrelated to drug. This incidence 
of AEs was similar to their respective healthy age- and sex-
controlled controls. Based on this study, no dose adjustments 
were recommended in patients with renal insufficiency.83 
Administration of 25 mg of alogliptin to 8 subjects with moder-
ate hepatic impairment did not result in any serious AEs.84
Theoretical issues
There are theoretical concerns85 stemming from the ubiquitous 
nature of DPP-4 enzyme presence: namely, this membrane-
associated protein is present in many tissues including kidneys, 
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and natural killer cells.86 DPP-4 has two major functions: 
a) enzymatic action that includes cleavage of oligopeptides 
and b) messenger action by activation of intracellular signaling 
pathways.87 While DPP-4 inhibitors do not affect the signaling 
action, there is a concern that inhibition of enzymatic action 
on regulatory peptides may produce unforeseeable AEs. Enzy-
matic action involves cleavage of oligopeptides and regulating 
metabolism and activation of peptides such as YY (involved 
in gastrointestinal functions), neuropeptide Y (involved in 
regulation of food intake) and brain-derived natriuretic pep-
tide (BNP) (involved in vasodilatation, natriuresis). Clinical 
consequences of blockade of these peptides are not obvious at 
this time but warrant long-term follow up. In addition, DPP-4 
protein has a role in T-cell mediated immune response. This 
raises concerns of possible side effects, related to reduced NK 
and T-cell function.75
Conclusions
Alogliptin is a new addition to incretin based therapies for 
type 2 diabetes. Like other agents in the DPP-4 inhibitor class, 
it offers good tolerability, lack of severe hypoglycemia, and 
weight neutrality as major advantages. In addition, thus far 
it appears to be safe for use in patients with co-morbidities 
such as heart failure and renal failure. In as much as endog-
enous GLP-1 has a beneficial effect on beta-cell mass, there 
is a hope that the DPP-4 inhibitor class might have such a 
benefit. That, however, has yet to be proven, not only for 
alogliptin but for other members of the DPP-4 class.85 On 
the other hand, alogliptin, like other DPP-4 inhibitors, is a 
new and hence costly agent of only modest efficacy. Mean 
HbA1c reductions of 0.5% to 0.8% seen with alogliptin and 
other DPP-4 inhibitors are markedly inferior to the 1.0% to 
2.0% reductions seen with metformin or sulfonylurea therapy 
and 1.5% to 3.5% reductions with addition of insulin therapy. 
The weight loss seen with GLP-1 agents does not occur with 
the current DPP-4 inhibitors. However, because of the low 
incidence of hypoglycemia and other side effects, the DPP-4 
inhibitors have a place in treatment of vulnerable patients, 
such as the elderly.
At this time, there is a lack of long-term safety data for 
alogliptin and other DPP-4 inhibitors, especially those related 
to generalized DPP-4 inhibition. Studies of longer duration 
and careful postapproval surveillance are needed to assess 
the safety of alogliptin. Undoubtedly such studies will pro-
ceed to assess long-term cardiac events in alogliptin-treated 
patients. Such large-scale studies should clarify the role of 
alogliptin in the armamentarium of therapies we use to treat 
type 2 diabetes mellitus.
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